À propos de cet article
Article Category: original-paper
Publié en ligne: 17 sept. 2021
Pages: 395 - 400
Reçu: 24 juin 2021
Accepté: 09 août 2021
DOI: https://doi.org/10.33073/pjm-2021-039
Mots clés
© 2021 Ayşenur Sümer Coşkun et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Descriptive variables related to patients.
| Demographic variables | N or X | % |
|---|---|---|
| Gender | ||
| Female | 8 | 25.0 |
| Male | 24 | 75.0 |
| Age (year) | 73.50 (52-94) | 73.43 ± 10.14 |
| 50-59 | 4 | 12.5 |
| 60-79 | 16 | 50.0 |
| ≥ 80 | 12 | 37.5 |
| BMI | ||
| Female | 28.89 (20.41-44.44) | |
| Male | 27.68 (20.76-44.98) | |
| Smoking status | ||
| Female | 2 | 25.0 |
| Male | 14 | 58.33 |
Isolation of fungi from the clinical specimens.
| Specimen | Fungal isolate | % |
|---|---|---|
| Blood | 16 | 23.2 |
| Aspirate | 12 | 17.4 |
| Urine | 29 | 42.1 |
| Urine + blood | 8 | 11.6 |
| Aspirate + blood | 3 | 4.4 |
| Aspirate + urine | 1 | 1.3 |
Distribution of fungal species in blood, tracheal aspirate, and urine cultures.
| Fungus types | Fungal isolate | Blood | Tracheal aspirate | Urine |
|---|---|---|---|---|
| Total: 16 | Total: 12 | Total: 29 | ||
| 20 (35.08) | 5 (31.25) | 4 (33.33) | 11 (37.93) | |
| 18 (31.58) | 4 (25.00) | 0 (0.00) | 14 (48.27) | |
| 14 (24.56) | 7(43.75) | 3 (25) | 4 (13.79) | |
| 3 (5.28) | 0 (0.00) | 3 (25) | 0 (0.00) | |
| 1 (1.75) | 0 (0.00) | 1 (8.34) | 0 (0.00) | |
| 1 (1.75) | 0 (0.00) | 1 (8.34) | 0 (0.00) |
Distribution of candidemia cases by hospitalization days.
| Mean ± SD | N | N (%) |
|---|---|---|
| 1-30days | 4 | 25 |
| > 30 days | 12 | 75 |
Antibiotics used by patients with fungal infection and days.
| Used antibiotics groups | Number of patients | Days of using antibiotic before fungal infection |
|---|---|---|
| Carbapenem | 32 (100%) | 17 ± 12.52 |
| Glycopeptide | 32 (100%) | 13 ± 7.4 |
| Linezolid | 23 (71.87%) | 10 ± 7.30 |
| Quinolone | 11 (33.3%) | 14 ± 7.20 |
| Tigecycline | 8 (24.24%) | 12 ± 5 |
| Aminoglycoside | 2 (6.06%) | 10 ± 2.3 |
Distribution of fungal infection cases based on accompanying diseases.
| Accompanying disease | Number of patients |
|---|---|
| Diabetes mellitus | 11 (34.4) |
| Cardiovascular disease | 22 (68.8) |
| Respiratory disease | 6 (18.8) |
| Neurological disease | 11 (34.4) |
| Renal disease | 1 (3.1) |
Distribution of fungal infection cases by risk factors.
| Number of Patients | Fungal Isolate | |
|---|---|---|
| Parenteral nutrition | ||
| No | 25 (78.1) | 45 (78.95) |
| Yes | 7 (21.9) | 12 (21.05) |
| Steroid use | ||
| No | 20 (62.5) | 44 (77.19) |
| Yes | 12 (37.5) | 13 (22.81) |
| ICU insulin use | ||
| No | 12 (37.5) | 24 (42.11) |
| Yes | 20 (62.5) | 33 (57.89) |
| Central venous catheter | ||
| No | 14 (43.75) | 45 (78.95) |
| Yes | 18 (56.25) | 12 (21.05) |